52212-02-9
基本信息
哌可松
4,4'-[(2Β,3Α,5Α,16Β,17Β)-3,17-雙(乙酰氧基)雄甾烷-2,16-亞基]雙(1,1-二甲基哌嗪錨)二溴化物
阿端
溴化吡哌考尼
pipecuronium bromide
4,4'-[(2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetoxy)androstane-2,16-diyl]bis[1,1-dimethylpiperazinium] dibromide
PIPECURIUM BROMIDE
Pipecuronium
PIPECURINIUM BROMIDE
4,4'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-Bis(acetyloxy)androstane-2,16-diyl)bis(1,1-dimethyl-piperazinium) dibromide
4,4’-[(2β,3α,5α,16β,17β)-3,17-Bis(acetoxy)andrc~tane-2,16-diyl]bis(1,1-dimethylpiperazinium)dibromide
Ardtm
Pipecuriurn Brmnide
RGH-1106
[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-2,16-bis(4,4-dimethyl-2,3,5,6-tetrahydropyrazin-1-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate dibromide
Androstane, piperazinium deriv.
Arduan
Piperazinium, 4,4'-[(2b,3a,5a,16b,17b.)-3,17-bis(acetyloxy)androstane-2,16-diyl]bis[1,1-dimethyl-, bromide (1:2)
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
應(yīng)用領(lǐng)域
制備方法
90g化合物(I)溶于500ml苯中,在冷卻和攪拌下,于1h內(nèi)加入92g過(guò)苯甲酸在1000ml苯中的溶液,在室溫下放置5h。反應(yīng)液用冰冷卻過(guò)的氫氧化鈉溶液洗,然后水洗,無(wú)水硫酸鎂干燥。減壓濃縮,剩余物用乙醚重結(jié)晶,得80g化合物(Ⅱ),收率81%,熔點(diǎn)182~184℃。
20g化合物(Ⅱ)溶于100ml N-甲基哌嗪和30ml水的混合液,在氮?dú)庵谢亓?0h。減壓蒸出過(guò)量的N-甲基哌嗪,剩余物和2倍量的乙腈混合,沸騰回流數(shù)分鐘。冷至0℃,過(guò)濾析出的白色結(jié)晶,真空干燥至恒重,得19g化合物(Ⅲ),收率63%,熔點(diǎn)199~201℃。
10.6g化合物(Ⅲ)溶于50ml四氫呋喃和50ml甲醇的混合液,加入9g過(guò)量的硼氫化鈉,攪拌6h。減壓蒸出溶劑,剩余物溶于氯仿。先用2%氫氧化鈉溶液洗,然后用水洗。干燥后蒸出溶劑,剩余物用氯仿和丙酮混合液重結(jié)晶,得9.3g化合物(Ⅳ),收率91%,熔點(diǎn)264~267℃。
5.8g化合物(Ⅳ)溶于20ml乙酸酐和5ml乙酸的混合液,加入0.5g氯化鋅,在室溫下攪拌3h。反應(yīng)液傾人250ml水,于0℃放置。過(guò)濾出沉淀,溶于乙醚,用水洗至中性。蒸去溶劑,再用正己烷重結(jié)晶,得5g化合物(V),收率71%,熔點(diǎn)128~130℃。
37.4g化合物(V)和16g溴甲烷溶于1300ml丙酮,在室溫下保持30h。過(guò)濾析出的結(jié)晶,用二氯甲烷和丙酮的混合液來(lái)提純,得48g哌庫(kù)溴銨,收率92%,熔點(diǎn)262~264℃(分解)。
最后一步反應(yīng)如下。4g化合物(V)溶于40ml二氯甲烷和20ml硝基甲烷的混合液中,加入9ml溴甲烷。在壓力管中于室溫下放置2d。過(guò)濾除去三甲基化的溴化物副產(chǎn)物。濾液用乙醚稀釋,過(guò)濾形成的固體,用二氯甲烷和乙醚混合液重結(jié)晶,得哌庫(kù)溴銨。
常見問(wèn)題列表
nAChR
Sugammadex has a high affinity for Pipecuronium bromide. As Pipecuronium bromide is about 6 to 7 times more potent than Rocuronium, fewer molecules are required to achieve a comparative blockade than in the case of Rocuronium.
The average ED
95
is 0.045mg/kg (0.035-0.059 mg/kg) of Pipecuronium bromide, the onset of action varies between 2 and 6.3 minutes, depending on the dose and the background anesthesia. Pipecuronium bromide does not liberate histamine, it has no cardiovascular side effects even in doses of 3× ED
95
, and anaphylaxis does not appear to be a problem.
Carboxymethylated γ-cyclodextrin shows efficient and complete reversal of the Pipecuronium bromide induced neuromuscular block in an ex vivo rat diaphragm experiment.